FR2139M - - Google Patents

Download PDF

Info

Publication number
FR2139M
FR2139M FR901889A FR901889A FR2139M FR 2139 M FR2139 M FR 2139M FR 901889 A FR901889 A FR 901889A FR 901889 A FR901889 A FR 901889A FR 2139 M FR2139 M FR 2139M
Authority
FR
France
Prior art keywords
hemostatic
preparations
peanuts
peel
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR901889A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spofa Sdruzeni Podniku Pro Zdravotnickou Vyrobu
Spofa Vereinigte Pharma Werke
Original Assignee
Spofa Sdruzeni Podniku Pro Zdravotnickou Vyrobu
Spofa Vereinigte Pharma Werke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spofa Sdruzeni Podniku Pro Zdravotnickou Vyrobu, Spofa Vereinigte Pharma Werke filed Critical Spofa Sdruzeni Podniku Pro Zdravotnickou Vyrobu
Priority to FR901889A priority Critical patent/FR2139M/fr
Application granted granted Critical
Publication of FR2139M publication Critical patent/FR2139M/fr
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

RÉPUBLIQUE FRANÇAISEFRENCH REPUBLIC

MINISTERE DE L'INDUSTRIEMINISTRY OF INDUSTRY

SERVICE de la PROPRIÉTÉ INDUSTRIELLEINDUSTRIAL PROPERTY SERVICE

BREVET SPÉCIAL DE MÉDICAMENTSPECIAL MEDICINAL PATENT

P.y. n° 901.889 Classification internationaleP.y. No. 901.889 International Classification

N° 2.139 M A 61 kN ° 2.139 M A 61 k

Hémostatique.Hemostatic.

Société dite : SPOFA, Sdruzeni podniku pro zdravotnickou vyrobu résidant en Tchécoslovaquie.Company known as: SPOFA, Sdruzeni podniku pro zdravotnickou vyrobu residing in Czechoslovakia.

Demandé le 25 juin 1962, à 16" 47m, à Paris.Requested June 25, 1962, at 16 "47m, in Paris.

Délivré par arrêté du 12 novembre 1963.Issued by decree of November 12, 1963.

[Bulletin officiel de la Propriété industrielle [B.S.M.], n° 50 de 1963.)[Official Bulletin of Industrial Property [B.S.M.], No. 50 of 1963.)

Il est connu dans la thérapeutique de faire usage de préparations dites hémostatiques dans le but de stopper le saignement.It is known in therapy to use so-called hemostatic preparations for the purpose of stopping bleeding.

Jusqu'ici les effets thérapeutiques de ces préparations étaient assez limités sur le plan de la thérapeutique générale.So far the therapeutic effects of these preparations were quite limited in terms of general therapy.

En effet les pouvoirs hémostatiques des préparations thromboplastiques sont, pour les cas de traitement généraux, incertains, les effets locaux étant relativement satisfaisants.In fact, the haemostatic powers of thromboplastic preparations are, for general treatment cases, uncertain, the local effects being relatively satisfactory.

On a constaté des analogies entre ces « préparations » et les préparations non spécifiques destinées à exciter les processus hémocoagulants, telles que par exemple les solutions hypertoniques de chlorure de sodium, donnent tout particulièrement un exemple de cet effet.Similarities have been found between these "preparations" and non-specific preparations intended to stimulate hemocoagulant processes, such as, for example, hypertonic solutions of sodium chloride, give a very particular example of this effect.

Il a été également prévu l'administration de vitamines et de substances destinées à consolider les parois de vaisseaux, celles-ci étant particulièrement employées dans les cas où le système sanguin souffrirait de dégénérescence locale.Provision has also been made for the administration of vitamins and substances intended to consolidate the walls of vessels, these being particularly employed in cases where the blood system suffers from local degeneration.

Les préparations vasoconstrictrices ont fait leurs preuves pratiquement, uniquement pour des applications locales, les applications générales sont souvent inefficaces.Vasoconstrictor preparations have proven themselves practically, only for topical applications, general applications are often ineffective.

L'utilisation de la 5-hydroxytryptamine se révèle peu efficace. On a également fait usage de dérivés sanguins contenant à concentration élevée des facteurs de coagulation, ces préparations sont coûteuses et les résultats en sont incertains.The use of 5-hydroxytryptamine proves to be ineffective. Blood derivatives containing high concentration of coagulation factors have also been used, these preparations are expensive and the results are uncertain.

Jusqu'ici le plasma et ses fractions étaient le seul moyen hémostatique utilisé dans la thérapeutique substitutive des coagulopathies congénitales.Until now plasma and its fractions were the only haemostatic means used in the replacement therapy of congenital coagulopathies.

La plupart des préparations hémostatiques couramment employées n'exercent leurs effets que pour une application parentérale.Most of the hemostatic preparations currently used exert their effects only for parenteral application.

De ce fait la thérapeutique substitutrice exigera le séjour du patient dans un hôpital, en effet il sera nécessaire d'appliquer les médications par voie parentérale sous la forme d'application intraveineuse.Therefore, replacement therapy will require the patient to stay in a hospital, as it will be necessary to apply parenteral medications in the form of intravenous application.

De plus le matériel de transfusion devra être frais et particulièrement bien entretenu, ce qui évidemment relèvera le coût du traitement et compliquera celui-ci.In addition, the transfusion equipment must be fresh and particularly well maintained, which will obviously raise the cost of treatment and complicate it.

Pour remédier à ces inconvénients, l'invention concerne un procédé de préparation d'extraits de graine de YArachis hypogaea L., procédé caractérisé en ce qu'on dissout la pelure interne membraneuse et brune de YArachis hypogaea L. dans un solvant et que l'on concentre l'extrait obtenu par évaporation, ce qui permet notamment d'obtenir ledit extrait sous forme de poudre, de gelée ou autre.To remedy these drawbacks, the invention relates to a process for preparing seed extracts of Arachis hypogaea L., a process characterized in that the membranous and brown inner peel of the Arachis hypogaea L. is dissolved in a solvent and that the 'the extract obtained by evaporation is concentrated, which makes it possible in particular to obtain said extract in the form of powder, jelly or the like.

La plante arachis hypogaea L. dite cacahuète exerce une certaine activité hémostatique, la peau de ces cacahuètes et en particulier la pelure interne membraneuse, mince et brune présente une activité thérapeutique supérieure à la cacahuète.The so-called peanut arachis hypogaea L. plant exerts a certain hemostatic activity, the skin of these peanuts and in particular the membranous, thin and brown inner peel exhibits a therapeutic activity greater than that of peanuts.

Des expériences ont permis de constater que l'activité hémostatique de la pelure était d'environ 50 fois supérieure à celle de la graine.Experiments showed that the hemostatic activity of the peel was about 50 times that of the seed.

L'hémostatique conforme à l'invention est plus particulièrement obtenue par extraction des pelures membraneuses de Yarachis hypogaea L. l'extraction étant obtenue soit à l'aide de solvant organique miscible dans l'eau soit avec de l'eau.The haemostatic agent in accordance with the invention is more particularly obtained by extraction of the membranous peels of Yarachis hypogaea L. the extraction being obtained either using an organic solvent miscible in water or with water.

Les dissolvants organiques peuvent être des alcanols avec 1-3 atomes de carbone, soit l'alcool d'éthyle, ces dissolvants peuvent avantageusement être mis en solution dans l'eau.The organic solvents can be alkanols with 1-3 carbon atoms, or ethyl alcohol, these solvents can advantageously be dissolved in water.

Dans le procédé d'obtention de l'hémostatique on opérera de la manière suivante :In the process for obtaining the hemostatic agent, the following procedure will be carried out:

a. Mise en solution des pelures de cacahuètes dans le solvant (on travaillera avantageusement sous pression réduite).at. Dissolving the peanut peels in the solvent (advantageously working under reduced pressure).

b. On évaporera le résidu afin d'obtenir le produit sous la forme de poudre, de gouttes ou de gelée.b. The residue will be evaporated to obtain the product in the form of powder, drops or jelly.

Pour l'obtention de cet hémostatique on peut faire usage de pelure, soit de cacahuètes crues, soit de cacahuètes torréfiées, l'effet hémostatique de la préparation étant toujours semblable.To obtain this hemostatic, use can be made of the peel, either of raw peanuts or of roasted peanuts, the hemostatic effect of the preparation being always similar.

65 2191 0 73 031 365 2191 0 73 031 3

Prix du fascicule: 2 francsPrice of the booklet: 2 francs

[2.139 M] —[2.139 M] -

Des essais pharmacologiques ont démontré que cet extrait de la pelure brune des cacahuètes est très peu toxique et que le principe actif en est absolument inoffensif.Pharmacological tests have shown that this extract from the brown peel of peanuts is not very toxic and that the active principle is absolutely harmless.

Des essais cliniques ont permis de constater que l'hémostatique de la présente invention peut être administré le plus avantageusement sous forme de teinture, la dose maximum étant de 20 gouttes, cette opération étant répétée quatre à six fois par jour.Clinical trials have shown that the hemostatic agent of the present invention can most advantageously be administered in the form of a tincture, the maximum dose being 20 drops, this operation being repeated four to six times per day.

On a constaté dans ces conditions que l'activité hémostatique était maximum.It was found under these conditions that the hemostatic activity was maximum.

On s'est servi de l'hémostatique conforme à l'invention pour stopper les saignements de toutes origines et notamment chez les hémophiles.The hemostatic agent in accordance with the invention was used to stop bleeding of all origins and in particular in hemophiliacs.

Exemple de préparation. — On extrait 200 g des pelures membraneuses internes, brunes des graines de la plante dite Arachis hypogaea L. dites « cacahuètes » obtenues en pelant les cacahuètes doucement grillées à l'aide de 2 000 g d'alcool d'éthyle de 96 % à la température normale pendant 96 heures pendant quatre jours. On agite intensivement le mélange pendant les premières huit heures de chaque jour, tandis qu'on laisse reposer le mélange chaque jour les 16 h subséquentes. On écarte les pelures de l'extrait par filtration et on concentre le filtratum par évaporation d'alcool d'éthyle sous pression réduite à une température doucement élevée. On dilue ensuite éventuellement le résidu d'évaporation par l'alcool d'éthyle de 96 % jusqu'à ce qu'on obtienne un volume ayant poids de 100 g. La préparation ainsi faite représente l'hémostaticum demandé exerçant un effet déjà décrit.Example of preparation. - 200 g of the internal, brown membranous peels are extracted from the seeds of the plant known as Arachis hypogaea L. called "peanuts" obtained by peeling the gently roasted peanuts using 2000 g of ethyl alcohol of 96% to normal temperature for 96 hours for four days. The mixture is stirred intensively for the first eight hours of each day, while the mixture is allowed to stand each day for the subsequent 16 hours. The peels of the extract are removed by filtration and the filtrate is concentrated by evaporation of ethyl alcohol under reduced pressure at a gently elevated temperature. The evaporation residue is then optionally diluted with 96% ethyl alcohol until a volume having a weight of 100 g is obtained. The preparation thus made represents the requested hemostaticum exerting an effect already described.

Bien entendu l'invention n'est pas limitée aux exemples de réalisation ci-dessus décrits pour lesquels on pourra prévoir d'autres modes et d'autres formes de réalisation sans pour cela sortir du cadre de l'invention.Of course, the invention is not limited to the embodiments described above for which other embodiments and other embodiments could be provided without thereby departing from the scope of the invention.

RÉSUMÉABSTRACT

A titre de médicament nouveau, un hémostatique caractérisé en ce qu'il se compose d'un extrait de la pelure de YArachis hypogaea L., ce qui permet d'arrêter les épanchements sanguins, notamment chez les hémophiles.As a new drug, a hemostatic agent characterized in that it consists of an extract of the peel of the Arachis hypogaea L., which makes it possible to stop blood effusions, in particular in hemophiliacs.

Société dite : SPOFA,Company known as: SPOFA,

Sdrbzeni podniku pro zdravotnickou vyrobu Par procuration :Sdrbzeni podniku pro zdravotnickou vyrobu By proxy:

Bert & de KeravenantBert & de Keravenant

AVIS DOCUMENTAIRE SUR LA NOUVEAUTÉDOCUMENTARY NOTICE ON THE NEW FEATURE

Documents susceptibles de porter atteinte à la nouveauté du médicament :Documents likely to affect the novelty of the medicinal product:

— Chemical Abstracts, volume 55, page 9598 a (1961) cite : « Thromb. et Diath. Haem. », T. Astrup, volume 5, pages 329-340 (1960).- Chemical Abstracts, volume 55, page 9598 a (1961) quotes: "Thromb. and Diath. Haem. », T. Astrup, volume 5, pages 329-340 (1960).

Le présent avis a fait l'objet d'observations présentées par le titulaire.This opinion was the subject of observations presented by the holder.

Pour la vente des fascicules, s'adresser à I'Imprimerie Nationale, 27, rue de la Convention, Paris (15*;.To sell the booklets, contact the Imprimerie Nationale, 27, rue de la Convention, Paris (15 * ;.

FR901889A 1962-06-25 1962-06-25 Expired FR2139M (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR901889A FR2139M (en) 1962-06-25 1962-06-25

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR901889A FR2139M (en) 1962-06-25 1962-06-25

Publications (1)

Publication Number Publication Date
FR2139M true FR2139M (en) 1963-12-13

Family

ID=27589491

Family Applications (1)

Application Number Title Priority Date Filing Date
FR901889A Expired FR2139M (en) 1962-06-25 1962-06-25

Country Status (1)

Country Link
FR (1) FR2139M (en)

Similar Documents

Publication Publication Date Title
Bhakta et al. Hepatoprotective activity of Cassia fistula leaf extract
EP0287488B1 (en) Medicament, dietary product and hygienic product in the form of a powdery composition obtained by adsorption of the active agents on a rapidly dissolving sugar, and process for the preparation of this composition
JP2000169384A (en) Composition for suppressing or lowering blood sugar level
FR2698791A1 (en) New extracts of cucurbita sp., Process for their preparation and medicines and cosmetics containing them.
LU85973A1 (en) THERAPEUTIC USE OF GM1 IN SEVERE CEREBRAL PATHOLOGIES DUE TO ISCHEMIA
FR2460669A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON RIFAMYCIN SV AND ITS SALTS ADAPTED FOR THE TREATMENT OF ARTICULAR RUMATISM AND PROCESS FOR THEIR PREPARATION
WO1984000688A1 (en) Ribosomal rna-based immunostimulating preparations and process for the preparation of rna
JP2010024208A (en) Ucp2 expression promotor
FR2139M (en)
LU82013A1 (en) NOVEL LYOPHILIZED POWDERS CONTAINING THIAZOLIDINE-4-CARBOXYLIC ACID SALT AND PROCESS FOR THEIR PREPARATION
FR2770228A1 (en) PROCESS FOR OBTAINING PROANTHOCYANIDINE OLIGOMERS BY BIOFERMENTATION AND THEIR USE IN COSMETIC, DIETETIC, PHARMACEUTICAL, CHEMICAL AND FOOD COMPOSITIONS
FR2922110A1 (en) USE OF A POWERFUL PRODUCT OF ZINGIBER OFFICINAL RHIZOMES EXTRACT IN THE TREATMENT OF A DISEASE ASSOCIATED WITH HELICOBACTER PYLORI
EP0342139B1 (en) Use of arginine aspartate for the manufacture of a medicament for treating certain inflictions of the memory
JP2727096B2 (en) Anti-dermatophyte
KR960700064A (en) Prostate Extract Supplemented with Zinc
CN1210033C (en) Immunodepressive medicine and its preparing process and application
JPS63316733A (en) Antiviral agent
FR2802818A1 (en) Preparation of concentrated terpenoid extract from birch bark, useful as dermopharmaceutical and cosmetic antiinflammatory compositions
JPS6150922A (en) External drug for skin containing extracted component of "oubaku"
CH630803A5 (en) Medicinal preparations, for the treatment of hypercholesterolaemia in particular
CN107753532A (en) A kind of soursop root extract and its anti-diabetes use
WO1994015626A9 (en) COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, CONTAINING A VISMIA EXTRACT
FR2622800A1 (en) Process for preparing a product for combatting viral complaints, especially cutaneomucosal viral complaints, pharmaceutical compositions and medicaments obtained using this process
RU2828000C1 (en) Method for preparing agent having hepatoprotective and choleretic effect
JPH11335293A (en) Cell activator, method for preparing cell activator, and external preparation for skin